Dermira Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 10, 2016 06:30 ET
|
Dermira, Inc.
- Positive Topline Results for DRM01 Phase 2b Acne Trial Reported; Phase 3 Program Planning Underway - Announcement of Topline Results for DRM04 Phase 3 Hyperhidrosis Pivotal Trials Expected in...
Dermira Announces Positive Topline Phase 2b Clinical Trial Results for DRM01 in Patients with Facial Acne Vulgaris
May 10, 2016 06:00 ET
|
Dermira, Inc.
- Safety and Efficacy Data Confirm Results from Previous Phase 2a Trial - DRM01 Phase 3 Clinical Program Planning Underway - Management to Host Webcast and Conference Call Today at 5:30 a.m....
Dermira’s Co-founder and Chief Medical Officer, Eugene A. Bauer, M.D., Receives Presidential Citation from the American Academy of Dermatology
March 14, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
March 03, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Report Fourth Quarter and Full Year 2015 Financial Results
March 01, 2016 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present at Cowen and Company 36th Annual Health Care Conference
March 01, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis
February 29, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Completes Patient Enrollment for Third CIMZIA® (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program and Updates Guidance for Release of Topline Data
January 08, 2016 01:00 ET
|
Dermira, Inc.
Enrollment for All Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Plaque Psoriasis Completed Dermira Plans to Announce Topline Data for Phase 3 Trials by End of First Quarter...
Dermira Added to NASDAQ Biotechnology Index
December 15, 2015 07:00 ET
|
Dermira, Inc.
MENLO PARK, Calif., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to...
Dermira Announces Poster Presentation on DRM01 in Acne at World Congress of Dermatology
June 02, 2015 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., June 2, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and...